Eli Lilly and Company (NYSE: LLY) believes it is inaccurate to imply that any single factor — including medication — was the cause of the unfortunate death of the patient profiled in New York Times – Jan_4.
The Food and Drug Administration (FDA) today is announcing the approval of Slentrol (dirlotapide), a prescription drug for the management of obesity in dogs. Slentrol reduces appetite and fat absorption to produce weight loss. A veterinarian will determine whether the dog should be treated, based on the dog’s weight and general health.
Genentech, Inc. (NYSE: DNA) announced encouraging results from a randomized Phase II study comparing pertuzumab plus gemcitabine to gemcitabine alone in women with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Data from the study will be submitted for presentation at an upcoming medical meeting.
Two drugs once commonly used to treat Parkinson’s disease, pergolide and cabergoline, produce heart valve defects in as many as a quarter of the patients who use them, Italian and German researchers reported today.
In the most comprehensive study of its kind, researchers have found that the inpatient length of stay for youth with mental illness fell more than sixty percent between 1990 and 2000, despite concurrent increases in illness severity and self-harm, and declining transfers to intermediate and inpatient care within the same population.
Sleepiness and sleep deprivation have long been associated with an increased risk of injury. However, the results of a recent study by a University of Missouri-Columbia researcher suggest that this commonly accepted theory might not be true.
A new study on risk factors of new-onset diabetes mellitus (NODM) following liver transplant found that a history of obesity, impaired fasting glucose and hepatitis C infection (HCV) paired with the use of a particular immunosuppressant are associated with an increased risk of NODM. Since all of these factors can be detected prior to undergoing a transplant, treatment should be tailored to the patient’s risk.
“Prioritizing nanotechnology risk research isn’t rocket science,” said Project on Emerging Nanotechnologies chief scientist Andrew Maynard. Dr. Maynard’s remark is in his testimony today before the federal government’s first public meeting focused exclusively on research needs and priorities for the environmental, health and safety risks of engineered nanoscale materials.
Researchers at Johns Hopkins have discovered that a tiny piece of genetic code apparently goes where no bit of it has gone before, and it gets there under its own internal code.
Estrogen regulates the brain’s energy metabolism in the same way as the hormone leptin, leading the way to a viable approach to tackling obesity in people resistant to leptin, researchers at Yale School of Medicine report in the Dec_31 online issue of Nature Medicine.